Clinical trial NCT06720129: The Application Effect of Modified Pressure-Reducing Fixation Protective Nasal Strip in the Nursing Care of Patients Receiving High-Flow Nasal Cannula Therapy
Official title: The Application Effect of Modified Pressure-Reducing Fixation Protective Nasal Strip in the Nursing Care of Patients Receiving High-Flow Nasal Cannula Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: High-Flow Nasal Cannula Therapy
Keywords: HFNC
pressure ulcer
patient comfort
Modified Pressure-Reducing Fixation Protective Nasal Strip
nursing efficacy
Lead sponsor: Wuxi Ninth People's Hospital
Sponsor class: OTHER_GOV
First posted: 2024-12-06
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study was a prospective, randomized controlled trial that included 60 patients receiving high-flow nasal cannula (HFNC) therapy. Participants were randomly divided into two groups: the observation group (n=30), which used a modified decompression fixation protective patch, and the control group (n=30), which received hydrocolloid dressing protection in addition to standard care. The study compared general demographic data, the interval time between changing fixation straps, the times of adjusting the catheter position, the effectiveness of skin management, the number of ineffective oxygenation attempts, the incidence of adverse events, and patient comfort scores between the two groups.


Eligibility criteria: Inclusion Criteria:

* 1. Meet the diagnostic criteria for respiratory failure, worsening dyspnea, acute exacerbation of chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and congestive heart failure.
* 2. No severe cognitive impairment.
* 3. Good compliance and being able to actively cooperate with the investigation.
* 4. No concurrent metabolic diseases.

Exclusion Criteria:

* 1. Patients with severe respiratory failure, severe arrhythmias, concurrent pneumothorax, coma upon admission, or persistent vomiting.
* 2. Patients with severe liver failure, kidney failure, or other severe systemic diseases.
* 3. Patients with severe cognitive impairment who are unable to understand or comply with the study requirements.
* 4. Patients with severe hemodynamic instability.
* 5. Patients with allergies to oxygen therapy or protective patch materials.

Primary outcomes:
measure: Interval Time for Changing the Fixation Strap
timeFrame: The time from receiving high-flow nasal cannula (HFNC) therapy to removal as per medical advice. up to a month.
measure: Times of Adjusting the Catheter Position
timeFrame: Data were collected every three days from the initiation of high-flow nasal cannula (HFNC) therapy until its removal as per medical advice. up to a month.
measure: Effectiveness of skin management
timeFrame: The time from receiving high-flow nasal cannula (HFNC) therapy to removal as per medical advice. up to a month.
measure: Incidence of Ineffective Oxygenation
timeFrame: The time from receiving high-flow nasal cannula (HFNC) therapy to removal as per medical advice. up to a month.
Secondary outcomes:
measure: Comparison of Comfort Levels
timeFrame: Assessed on the 3th day after the start of the experiment
measure: Adverse Event Incidence
timeFrame: The time from receiving high-flow nasal cannula (HFNC) therapy to removal as per medical advice. up to a month.
Other outcomes:
measure: Gender
timeFrame: The time from admission to discharge. up to 6 weeks.
measure: Age
timeFrame: The time from admission to discharge. up to 6 weeks.
measure: Length of hospital stay
timeFrame: The time from admission to discharge. up to 6 weeks.
measure: Days of treatment use
timeFrame: The time from admission to discharge. up to 6 weeks.
Locations:
city: Wuxi
country: China
facility: Wuxi Ninth People's Hospital
state: Jiangsu
Study officials:
References: